As of July 1, 2024, 178 Registry patients fulfilled inclusion criteria for analysis (male: 55.7%; mean±SD age at MG diagnosis: 54.7±19.0yrs) with 89, 49, and 40 patients in the eculizumab, ravulizumab, and eculizumab-to-ravulizumab subgroups, respectively. Statistically significant reductions (P<0.05) in mean scores were observed for all MG-ADL subdomains after C5IT initiation. Reductions from prior to C5IT to last assessment during C5IT treatment ranged from 41.0% to 53.0% (ocular), 49.9% to 73.1% (bulbar), 40.7% to 58.6% (respiratory), and 33.7% to 71.4% (limbs) across the 3 subgroups. The proportions of patients with complete or partial improvement in individual MG-ADL subdomains during C5IT treatment were similar between the eculizumab and ravulizumab subgroups: 60.7% and 63.3% (ocular), 58.4% and 59.2% (bulbar), 51.7% and 49.0% (limbs), and 33.7% and 26.5% (respiratory), respectively. Among the eculizumab-to-ravulizumab subgroup, the proportions of patients with complete or partial improvement in individual subdomains were 67.5% (ocular), 67.5% (bulbar), 65.0% (limbs), and 45.0% (respiratory) at last assessment during ravulizumab treatment. Results with extended follow-up will be presented.

These results from clinical practice show the broad benefit of complement C5 inhibition with eculizumab and ravulizumab in improving ocular, bulbar, respiratory, and limb function as indicated by MG-ADL subdomain score in patients with AChR-Ab+ gMG.